#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2023

### KNOW LABS, INC.

(Exact name of registrant as specified in its charter)

001
(Cor

Nevada (State or other jurisdiction of incorporation) 001-37479 (Commission File Number) 90-0273142

(IRS Employer Identification No.)

500 Union Street, Suite 810, Seattle, Washington

(Address of principal executive offices)

98101 (Zip Code)

<u>(206) 903-1351</u>

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, par value \$0.001	KNW	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01 Regulation FD Disclosure.

On October 31, 2023, Know Labs, Inc. (the "Company") issued a press release announcing it will present at the third annual Bernstein CGM Disruptors Conference, Thursday, November 2, 2023. At this virtual event organized by Bernstein Research, www.bernsteinresearch.com, attendees from across the globe will gather to discuss new developments in continuous glucose monitoring technology. On October 31, 2023, the Company released the presentation it will deliver at the conference. The presentation is furnished as Exhibit 99.1 to this report and can also be downloaded on the Company website, www.knowlabs.co.

The information furnished with this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
<u>99.1</u>	Know Labs Presentation, 3rd Annual Bernstein CGM Disruptors Conference
<u>99.2</u>	Press Release dated October 31, 2023. Filed herewith.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

- 2 -

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 31, 2023

KNOW LABS, INC.

/s/ Ronald P. Erickson Name: Ronald P. Erickson Title: Chairman of the Board



# **KNOW** LABS

**3rd Bernstein CGM Disruptors Conference** November 2, 2023

Pete Conley CFO & SVP IP Know Labs (NYSE American: KNW)

COPYRIGHT KNOW LABS, INC. 2023

# DISCLOSURE

#### CAUTION ABOUT FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that are based on the Company management's belefit and assumptions and on information currently available to the Company. All statements of historical facts are forward-looking statements. These statements relate to furne events or to the Company's faute financial performance and involve known and unknown take, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results. Involve forward-looking statements. Forward-looking statements, Forward-looking statements, Forward-looking statements, convention take, but are not limited to, statements about goals and strategies; future balances development, financial condition and results of operations expected colories in versus. Courts of operations expected colories expecting colories of expecting rungs of the company's and/or adiatability and expectitions regarding damands courd marked acceptance of our condition and results of operations expected colories of expecting rungs of the company's and/or adiatability in the statements are only predictions. You should not place and other factors may different from any forward looking statements, including collaries and other factors may course they involve forward-looking statements, social factors are only predictions. These statements are only predictions. These issues around a condition of the company adiation of the company and and on the factors and other factors may cause the company and and other factors may cause the company and and other factors and other factors may cause the company and and the company and and the company and the compan

General securities market uncertainties resulting in accommic considerations. Means unsease regarding the aforementioned gos-political considerations and increasing inflation has caused the United States and worklevide national securities markets to have undergone unprecedented stress due to the uncertainties of regarding the science of a securities markets science, increases in volumes due to flight to safety and governments. Justicesses, and the general population. These uncertainties have resulted in declines in all market sectors, increases in volumes due to flight to safety and governments accions to support the markets. As a result, until economic outlook has stabilized, the mark may not be available to the Company for purposes of ratiality equivalent. Show we not the able to obtain financing when required, in the amounts necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full, or on terms which are economically feasible, we may be unable to sustain the necessary to execute on our plans in full.

We need additional financing to support our technology development and ongoing operations, pay our debts and maintain ownership of our intellectual properties. We are currently operating at a loss and using substantial cash to fund our operations. We believe that our cash on hand will be sufficient to fund our operations through September 30, 2024. We will need additional financing to implement our business plan and to service our ongoing operations that we will be additional financing to implement our business plan and to service our ongoing maintend our operations. There can be no assume that we will be able to secure any meeded funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain financing to implement our business plan and to service our ongoing meeter and public equity offening, det financing and strategic collaborations. Debt financing is available, the terms or conditions would be acceptable to us. If we are unable to obtain financing to implement our business and and additional additionad additionad additional additional addit

We have a history of operating losses and there can be no assurance that we can achieve or maintain profitability. We have experienced net losses since inception. As of June 30, 2023, we had an accumulated definit of \$118,715,000 and net losses in the amount of \$12,853,000, \$20,071,000 and \$25,360,000 during the nine months ended June 30, 2023 and the years ended September 30, 2022 and the years ended September 30, 2022 and the years index of balance that we will ender work maintain profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and adversal fact the price of our common stock and our ability to raise capital. Our operating expenses may increase as we spend records on business, and if our revenue does not correspondingly increase, our operating results and financial condition will be the out ability to raise capital. Our operating expenses may increase as we spend records on business, and if our revenue does not correspondingly increase, our operating results and financial condition will be than our ability to end them our ability to raise capital and then ear term, or at all which would impair our ability to end them our ability to end aider our business and prospects in light of

# If we are unable to secure a sales and marketing partner or establish satisfactory sales and marketing capabilities at our company, we may not be able to successfully commercialize our technology. If we are not successful entering into appropriate collaboration arrangements or recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing our technology, which would adversely affect our business, operating results and marketing personnel activities of the sales and marketing personnel in the success of the efforts of these third parties. If we elect to establish a sales and marketing personnel in the success of the efforts of these third parties. If we elect to establish a sales and marketing personnel is not success of the efforts of these third parties. If we elect to establish a sales and marketing personnel is not strategic partners or leances include: - our inability to recruit and retain adoptate numbers of effective sales and marketing personnel. In addition, we must compare with established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retains adoptate numbers of effective sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and - uniforeseen costs and expenses associated with creating an independent sales and marketing organization.

Government regulatory approval may be necessary before some of our products can be sold and there is no assurance such approval will be granted. Our technology will have a number of potential applications in fields of use which will require pior governmental regulatory approval before the technology can be introduced to the marketplace. For example, we are exploring the use of our technology for certain medical diagnostic applications of what an initial focus on the monitoring of blood phoces. There is no assurance hat we will be evenesatif in developing glucose monitoring medical applications of our technology, prior clearance by the FDA and other governmental regulatory bodies will be required before the technology could be introduced to the marketplace. Our devices leverage Machine Learning (ML) and Artificial Intelligence (A) to process the masket data collected through the Bio/setting to assess that an event body dupose monitoring medical applications of our technology, prior clearance by the FDA and other governmental regulatory bodies will be required before the technology could be introduced not the marketplace. Our devices leverage Machine Learning (ML) and Artificial Intelligence (A) to process the masket data collected through the Bio/setting to be modified and improved tasks, prior devices leverage Machine Learning (ML) and Artificial Intelligence (A) to process the masket data collected through the Bio/setting such approval and be devices between tables the devices of the approximate to the explanations required by the FDA while recently responsed to a such approximate that and the applications requires that devices that and the marketplace. Our devices leverage Machine Learning method devices to the marketplace devices to the setting that the recent setting such approval would be obtained for a glucose monitoring update applications requires that device that applications requires that device that applications requires that device that the necessary regulatory approval and learnote prove devic

# WHAT'S HAPPENED SINCE LAST YEAR'S BERNSTEIN 2022 CONFERENCE?

### FY Sept 2023 In Review:

- 1. PRODUCT: Successful introduction of Gen 1 Product Prototype on June 7, 2023.
- **2.** SCIENTIFIC VALIDATION: Peer-Reviewed Publication in Sensors Journal of Proof-of-Principle Study in Collaboration with Mayo Clinic. Poster presentations at APS and AACE.
- **3.** CLINICAL ACCURACY: Demonstrated 11.27% MARD from data collected in normoglycemic and hyperglycemic ranges across 366 datasets, 3,300 reference points and ><u>1.7B</u> datapoints.
- **4. INTELLECTUAL PROPERTY:** Patents issued, pending and in-process increased from 89 to 246 YoY (+176% vs. market +35%, 5x market CAGR) reflecting our high rate of innovation. Ranked by IPCG #1 in the world for non-invasive blood glucose monitoring IP.
- STRATEGIC COLLABORATIONS: JDA discussions currently underway with potential biopharma, med device and consumer electronics partners.

COPYRIGHT KNOW LABS, INC. 2023

# **INTRODUCED JUNE 7, 2023**

# KnowU

2023: NI BGM & 2024: NI CGM

<u>Gen 1</u>: Place your palm or arm on the portable device for on-demand NI BGM data. "Computer mouse" form factor.


<u>Gen 2</u>: 50% smaller wearable NI CGM currently under development for early 2024 release. "AirPods case" form factor.




Generation 1 Prototype Device: A sophisticated research lab in your pocket.

COPYRIGHT KNOW LABS, INC. 2023

# WHY IT WORKS (and why others don't)



# HOW IT WORKS: More is More ... 3D Data Improves Clinical Accuracy



### <u>Three Orders of Magnitude Increase</u> of Volumetric <u>3D</u> <u>Voltage Data</u> Collected in <u>Real Time</u> versus Current <u>2D</u> CGMs

# HOW IT WORKS: Dexcom G7 versus KnowU - FDA Test Principles

### THE VOLTS HAVE IT: Two Different Models of "Glucose Voltmeters": Real-time Direct Reading of Blood Glucose Without the Proxy Latency of Current CGMs

- The Dexcom G7 system detects glucose levels from the fluid just beneath the skin (interstitial fluid) using a microneedle to a depth of 5 mm & .001 cc.
- The microneedle continuously measures glucose concentrations in the interstitial fluid via an enzymatic electrochemical reaction using glucose oxidase. Glucose oxidase catalyzes the oxidation of glucose and produces hydrogen peroxide, as a proxy for blood glucose.
- The production of proxy hydrogen peroxide <u>generates</u> an electrical current that is proportional to the interstitial glucose concentration which, using an algorithm, is converted to a glucose value.
- The KnowU system detects glucose levels in real-time across the "tissue stack" (interstitial fluid, capillary blood, venous blood, cellular glucose) using non-invasive <u>RF dielectric</u> (impedance measurement) spectroscopy to a depth of 12.7 mm & 5.4 cc.
- KnowU harnesses the dielectric properties of glucose, a polar molecule in the body, and its ability to store electrical energy in an electric field (known as permittivity).
- Using time frequency sweeps, KnowU rapidly scans a large range of RF frequencies and records voltage values detected at each frequency to quantify real-time blood glucose continuously.
- For each RF sweep, the KnowU returns a vector of voltage values representing the antenna's transmission coefficient (using S21, not S11) over its frequency of operation.

COPYRIGHT KNOW LABS, INC. 2023

# **CLINICAL TESTING PROTOCOL**

Data Collection Over 3 Hour Test

- The array of antennas sits approximately 1 mm away from the users' skin inside the plastic wall of the device with which the user is in contact. The patient's arm, hand, or other body part appropriate for the sensor must be against the device for the 22 second length of the frequency sweep.
- The sensor currently operates within a frequency range of roughly 500 to 1500 MHz, though it has the ability to operate between 300 and 4400 MHz so a larger range scan could be used in the future.
- To take a measurement, the sensor scans through the frequency range, currently using 0.1 MHz intervals so that 10,001 data points are collected per sweep, equals 445 data points per second (versus 30 data points per second for a pulse oximeter).




Using KnowU on Hand



Using KnowU on Forearm

COPYRIGHT KNOW LABS, INC. 2023

# FROM IN VITRO TO IN VIVO GLUCOSE TESTING




# TIMELINE OF VALIDATION STUDIES FROM IN VITRO TO IN VIVO

2021	•		22 202	3 -	•	TODAY
Manuscript	Proof of Principle with Mayo Clinic	Exploratory Clinical Study	Proof of Concept Clinical Study	Technical Feasibility Study	New Algorithm Refinement Study	Data Preprocessing Techniques Study
Description	Demonstrated the accuracy of Bio-RFID sensor in quantifying different analytes in vitro (liquid solution).	First indication that Bio-RFID could be an accurate alternative to FDA-cleared glucose devices.	Proof of concept ability to quantify blood glucose non- invasively using RF.	Demonstrates Bio- RFID can deliver stable, repeatable results in measuring blood glucose levels.		Improvement in machine learning model accuracy on ar expanded mixed cohort dataset.
Accuracy	Almost 100% in vitro accuracy	MARD 5.3%-6.7%	MARD 19.3%	MARD 20.6%	MARD 12.9%	MARD <u>11.3%</u>
# Participants	na	2	1	5	5	13
# Datasets	na	3	22	106	106	366
# Bio-RFID datapoints	na	<u>1.5M</u>	~183M	~430M	~430M	<u>~1.7B (</u> 3 order of magnitude)
# Reference Observations	na	75 Know Labs' Tech	~383	~1,555	~1,555	~3,311

COPYRIGHT KNOW LABS, INC. 2023

Past performance is not indicative of future results. There is no assurance that the development will have a successful outcome. Past performance is not indicative of future results. There is no guarantee that any specific objective will be achieved.




# **CLINICAL ACCURACY IN MIXED COHORT: July 2023**

Novel data preprocessing techniques in an expanded dataset improve ML model accuracy Reviewed By Members of Know Labs' Scientific Advisory Board

	Observations	MARD (%)	MAE (mg/dl)	±15%	±20%
Hypoglycemic (<70 mg/dl)	2 (<.3%)	n/a	n/a	n/a	n/a
Normoglycemic (70 – 180 mg/dl)	608 (91.4%)	10.76 ± 0.79	12.00 ± 0.82	75.5 ± 3.4	83.6 ± 2.9
Hyperglycemic (>180 mg/dl)	53 (8.3%)	15.92 ± 2.98	33.43 ± 6.51	58.5 ± 13.3	67.9 ± 12.6

- Demonstrates a test in which the patented RF dielectric (impedance) spectroscopy sensor was able to predict reference values of Dexcom G6® CGM continuously and non-invasively with a <u>MARD of 11.27%</u>
- Caveat: one limitation of this study is the requirement for <u>a larger and more diverse</u> <u>participant population</u>. All participants were healthy and did not have diabetes; indeed, 91.4% of the reference values were in the normoglycemic range



COPYRIGHT KNOW LABS, INC. 2023

Know Labs' Technology is in development, and there is no assurance that the development will have a successful outcome. Past performance is not indicative of future results. There is no guarantee that any specific objective will be achieved.

# **EXPECTED PATH TO MARKET**

 Key


 Completed FY 9/2018 - 2023

 Current FY 9/2023 - 2024


 Planned FY 9/2024 - 2026


	SENSOR INNOVATION	c	CONTROLLED LAB TESTING			REAL-WO		SCALE & COMMERCIAL SPECS	INTERNAL & FDA TRIALS	FDA CLEAF ANCE
	Optical sensing path dropped	Exploratory Stud (MARD 5.8% to 6							Are -	
Stationary Research System Miniaturiz	~200 RF antennas designed & tested									
	Miniaturization to Bio-RFID Sensor					iverse Populai ood Draw (Go	tion, People al: MARD <10%)			
		N=1	N=5 N=13	NN = 30	N = 30 Develop Customizable Algorithm					
GEN 1 Portable Research		Design & Build Gen 1 Device (12 Units)	System & Sensor Characterization (Wired + Wireless)	N=5 (pilot study)	Build Gen1 Device	Enviror	nment, Human rs, Diverse Pop			
System		JDA Opportunities (biopharma, medical device, and consumer electro					cs use cases)			
GEN 2 Portable Medical Device			Design & Build Gen 2 Device (earbuds case size)	System & S Characteriz (Wireless)		Build 1,000 Gen2 Devices	N>500 Diverse Population Study	N=1,000 Design Freeze	N=TBD FDA Trials (multiple)	Gen 2 Device Launch
GEN X					(N		ENERATIONS Intended Use(s), et	c.)	/	

# KNOW LABS IP STORY: IP Market is Growing Rapidly in NI BGM



# KNOW LABS IP STORY: Extending Our IP Leadership Beyond Just Market Growth





# STRATEGIC IP VALUE CREATION: Leadership & Interoperability

# F500-Class Strategic Development Partners Accelerate Our Speed to Market

#### HARDWARE - GENERATION 1 & 2 PROTOTYPES

#### ALGORITHM (DATA SCIENCE)



# FY 9/2024\* Goals

#### Introduce Gen 2 CGM device

- Wearable CGM at least 50% smaller than Gen 1 ("earbuds case size")
- Potential format for FDA submission

#### Further accelerate data collection and continue algorithm refinement

- Tens of billions of data points and reference points (IV, CGMs and finger sticks) internal and external research institutions
- · Achieve MARD under 10% in large mixed cohorts
- · Increase the generalizability of the RF sensor
- · Submit validation manuscripts to key global diabetes conference and peer-reviewed journals

#### Refine regulatory strategy

- Apply for FDA Breakthrough Designation (FY 9/2024)
- FDA De Novo Classification Preparation (FY 9/2025 / FY 9/2026)

#### Build upon current global IP leadership and interoperability in non-invasive blood glucose monitoring

Prepare organization for accelerated growth and go-to-market plan (FY 9/2025 / FY 9/2026)

#### Execute upon multiple JDA opportunities (core and non-core)

\* October 2023 to September 2024

This slide contains forward-looking statements that are based on Company management's beliefs and assumptions and on infor currently available to the Company. See page 2 for our full discussion of forward-looking statements. COPYRIGHT KNOW LASS, INC. 2023

Know Labs' Technology is in development, and there is no assurance that the development will have a successful outcome. Past performance is not indicative of future results. There is no guarantee that any specific objective will be achieved.

# Why Know Labs?

Emerging	Global	IP	Medical	Platform
Leader	Innovator	Leadership	Device	Technology
<ul> <li>NYSE American IPO September 15, 2022</li> <li>Below the radar - current Form 13F Institutional Ownership &lt;6%*. (25 institutions with 46 funds)</li> <li>~\$20M Market Cap versus &gt;\$30B Market Cap for CGM Incumbents, a factor of 1500x</li> <li>* Form 13Fs as of 6/30/2023</li> </ul>	<ul> <li>Highly differentiated approach to glucose monitoring with high specificity &amp; sensitivity</li> <li>Combination of radio and microwave spectroscopy monitors high resolution analyte data in real-time</li> <li>3D data collection</li> </ul>	<ul> <li>246 patents issued, pending and in- process filings worldwide</li> <li>Foundational patents cover more than 100 analytes</li> <li>System-level interoperability to enable new hybrid architectures with CGM incumbents</li> </ul>	<ul> <li>Highly accurate medical device to serve the needs of hundreds of millions</li> <li>Hundreds of tests proved that KnowU can measure blood glucose levels non-invasively</li> <li>High level of accuracy</li> </ul>	<ul> <li>Real-world commercialization opportunities across multiple industries</li> <li>100+ potential applications and use cases in medical diagnostics and beyond</li> <li>F500-class development partners to bring to products to market</li> </ul>











#### Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference, Details Significant Progress During the Past Year

SEATTLE – October 31, 2023 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, will present at the third annual <u>Bernstein CGM Disruptors Conference</u> on Thursday, November 2, 2023. Presenters and institutional investors from across the globe will gather virtually to discuss the latest developments in continuous glucose monitoring (CGM) technology.

Pete Conley, Chief Financial Officer, and Senior Vice President of Intellectual Property (IP) at Know Labs, will provide an update on the company's progress over the past year. Highlights include a significant expansion of the company's IP leadership in the non-invasive blood glucose monitoring category, with 246 patents issued, pending, and in process (a 176 percent increase year-over-year); the publication of several peer-reviewed reports on its clinical results; and the completed production of its <u>Generation 1</u> working prototype.

Mr. Conley will also provide development updates for the company's diagnostic technology platform and the path to bringing the first FDA-cleared non-invasive blood glucose monitor to the marketplace.

Throughout the year, Know Labs has remained focused on refinement of their prototype device and its algorithms, as well as external validation of the technology with its growing body of peer-reviewed evidence, which can be found at <u>www.knowlabs.co/research-and-validation</u>.

Interested parties can view Know Labs' Bernstein CGM Disruptors Conference presentation on the <u>company website</u>. Investor information can also be found at <u>www.knowlabs.co/investors</u>. For more information on Know Labs, visit <u>www.knowlabs.co</u>.

#### About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol "KNW." The Company's platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

#### Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company's fillings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements forward-looking statements are or guarantees of our website at www.knowlabs.co. The Company cautions readers not to place un

#### For Know Labs Media Inquiries Contact:

Matter Health Abby Mayo Knowlabs@matternow.com Ph. (617) 272-0592

Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co Ph. (206) 629-6414